SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present a poster at the 61stAmerican Society of Hematology (ASH) Annual Meeting & Exposition, which takes place Dec 7-10, 2019, in Orlando, Fl, and will deliver an oral presentation...
Category: News
Qpex Biopharma Announces Exercise of $20 Million Option by BARDA under its Other Transaction Authority (OTA) Agreement to Advance Multiple Products into Clinical Studies
SAN DIEGO, December 16, 2019 – Qpex Biopharma, Inc., a biopharmaceutical company dedicated to the discovery and development of innovative anti-infective therapies, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first agreement option, which will support advancing multiple programs into clinical studies.
Timetable Update
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Timetable update for the proposed Subscription and Placing Oxford, UK, and Cambridge, MA, US, 19 December 2019 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that, further to the announcement made on 6 December 2019 regarding a fundraising of approximately $50 million...
Venatorx Pharmaceuticals Joins the Alliance for Biosecurity
Malvern, PA, December 19, 2019 – Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available. “We welcome Venatorx...
Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), and Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a 5-year contract, with an option to...
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Oxford, UK, and Cambridge, MA, US, 17 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today reports its financial results and provides an update on its operational progress...
Notice of Q3 Results
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2019 on 17 December 2019 Oxford, UK, and Cambridge, MA, US, 16 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its...
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors
JERSEY CITY, N.J., Dec. 16, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of accomplished business development executive Philippe Tinmouth to its Board of Directors. Mr. Tinmouth brings over 20 years of experience across multiple business development and alliance management roles,...
SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., Dec. 12, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share of common stock and warrant to purchase one share of common stock were sold...
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced topline results from its Sulopenem for...